


PHARMACEUTICAL 2019



BIOSPECIFICS TECHNOLOGIES CORP Rank 4 of 363





PHARMACEUTICAL 2019



BIOSPECIFICS TECHNOLOGIES CORP Rank 4 of 363

The relative strengths and weaknesses of BIOSPECIFICS TECHNOLOGIES CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOSPECIFICS TECHNOLOGIES CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 105% points. The greatest weakness of BIOSPECIFICS TECHNOLOGIES CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 366%, being 329% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	98,234
Cost of Goods Sold	0
Intangible Assets	444
Liabilities, Current	2,504
Liabilities, Non-Current	0
Other Assets	1,414
Other Compr. Net Income	0
Other Expenses	4,744
Other Liabilities	0
Other Net Income	1,399
Other Revenues	32,961
Property and Equipment	0
Research and Development	757
Selling, General and Administrative Expense	8,806

Output Variable	Value in 1000 USD
Assets	100,092
Liabilities	2,504
Expenses	14,307
Revenues	32,961
Stockholders Equity	97,589
Net Income	20,053
Comprehensive Net Income	20,053
Economic Capital Ratio	366%

